Daily Cosmetic Research Analysis

BACKGROUND: Extramammary Paget's disease (EMPD) is a rare cutaneous mucinous adenocarcinoma primarily affect the penoscrotal skin, characterized by the presence of Paget cells scattered within the epidermis. The molecular features of Paget cells remain poorly understood. OBJECTIVES: To describe the genomic and transcriptomic landscape of penoscrotal EMPD, identify the driver mutation or core transcription factor through integrative analysis, identify biological markers and provide new insights for the pathogenesis of penoscrotal EMPD. METHODS: Whole exome sequencing was performed on penoscrotal EMPD tissues from 37 patients, of whom 28 patients also underwent RNA sequencing, and the findings was validated in an additional 72 patients, encompassing 120 multi-region tumor tissues to identify core transcription factors. The dysregulation was further confirmed by immunohistochemistry. RESULTS: Genomic landscape did not reveal FOXA1 or SPDEF mutations penoscrotal EMPD. Transcriptomic profiling identified the upregulation of lineage-specific transcription factors FOXA1 and SPDEF, along with their targeted genes AGR2 and MUC5AC. Upregulation of FOXA1, SPDEF and AGR2 without gene fusion were consistently replicated in the validation cohort. Further analysis of multiple tissue regions confirmed FOXA1 and SPDEF as driver transcription factors in penoscrotal EMPD. We identify key transcription factors regulating co-expressed modules FOXA1-SPDEF-AGR2, suggesting goblet cells features of penoscrotal EMPD. The immunohistochemistry confirmed the co-expression of FOXA1-AGR2 pattern in Paget cells. CONCLUSIONS: Our study provides novel insights into the molecular characteristics of Paget cells, and also highlights the critical role of FOXA1 in Paget cell development in EMPD.

BACKGROUND: Platysma prominence (PP) is characterized by vertical bands along the length of the neck and blunting of the jawline, impacting aesthetic appearance. No validated patient-reported outcome (PRO) measures are available to assess patient experiences specific to PP. OBJECTIVE: Develop and validate fit-for-purpose PRO measures that capture patient experiences with PP and treatment outcomes. METHODS: PRO measures were developed and validated in alignment with the FDA's patient-focused drug development guidance. Three interviews (concept elicitation [CE], RESULTS: "Bands" or a variation (e.g., cords, ridges, lines) were the most common terms used to describe PP, reported by 50% of participants. The most frequently reported psychosocial impacts were looking older than desired ( CONCLUSION: These PRO measures demonstrated content and psychometric validity and are ready for use in research and practice to better understand the impact of PP from the patient perspective. Platysma prominence (PP) is a condition that can negatively impact the appearance of the neck and lower face. It creates vertical bands that run from the jawline down to the lower neck. These vertical neck bands are noticeable when making certain facial expressions or when moving in certain ways (for example, laughing, smiling, exercising). PP may also negatively impact how defined the jawline looks. These effects can be bothersome to some people because they can make them appear old, sad, or angry. The goal of this research was to develop new questionnaires that measure how patients feel about the appearance of their neck and lower face before and after treatment, which can help measure how well PP treatments work. To develop these questionnaires, people with PP were interviewed to understand what concepts were most important to measure. The questionnaires were drafted based on the information provided by people with PP. Then, the people with PP were interviewed again to make sure the questionnaires were understandable and relevant. Next, the questionnaires were given to patients participating in a PP clinical trial. Their answers were used to confirm that the questionnaires were reliable and valid. Patient questionnaires are now ready for use to assess the impact of PP and improvement with treatment. For example, people can describe how satisfied or dissatisfied they are with PP treatment, how often PP negativity affects the appearance of their neck and lower face as well as how they feel, and how much PP bothers them.

OBJECTIVES: To evaluate patient-reported outcome measures (PROMs) of povidone-iodine rinse and chlorhexidine rinse for patients undergoing dental implant treatments, as well as their bacteriostatic efficacy. MATERIALS AND METHODS: Patients needing implant or bone augmentation surgery were randomized into two groups: povidone-iodine(PVP-I) and chlorhexidine(CHX). On the first day after surgery, pain levels were assessed by Numerical Rating Scale (NRS) to compare the two mouthwashes. At two weeks post-surgery, wound healing was evaluated using the early wound healing index. Finally, patient-reported outcome measures (PROMs) were employed to compare each mouthwash's flavor, texture, and whether it caused irritation or mucosal staining. The significance of intergroup differences was tested using both an intention to treat and a per-protocol analysis. RESULTS: A total of 83 patients(with a median age of 43, 49 females) were enrolled and randomized. In general, both rinses were similarly favorable in terms of patient comfort. Notably, the postoperative pain NRS was significantly lower in the PVP-I group (1.68 ± 0.82) than in the control group (2.55 ± 1.38, p < 0.01). Regarding to wound healing, there was no significant difference in the Early Healing Index (EHI) between the two groups (Z = 0.351, p = 0.725). Regarding PROMs, at day 7, the swelling reduction was significantly greater in the PVP-I group (p = 0.031). Additionally, fewer participants in the PVP-I group (7%) reported mucosal irritation compared to the CHX group (29%) (p < 0.05), while other PROMs showed no significant differences in both groups. CONCLUSIONS: Within the scope of this trial, PVP-I rinse demonstrated superior patient comfort (significantly lower postoperative pain intensity, less mucosal irritation, and greater swelling reduction at day 7) compared to CHX rinse, though both rinses showed comparable wound healing outcomes. PVP-I may serve as an alternative for dental implant therapy, but all mouthrinses should be used judiciously under clinical guidance. TRIAL REGISTRATION: The study protocol was registered at Chinese Clinical Trial Registry ( www.chictr.org.cn ) under registration number ChiCTR2500098491 on 10/03/2025 (retrospectively registered).